A good example all ‘cidp’ is not equal

July 23, 2010 at 3:02 pm

ms. Judy,

Your thread led me to do some research.

First, from the NIH: “We evaluated distal compound muscle action potential (CMAP) dispersion in 29 patients with anti-MAG/sulphated glucuronyl paragloboside (SGPG) neuropathy (titres > or = 12,800).”

So, your numbers at, or near, 12,000 fit this profile.

Full article: [url]http://www.ncbi.nlm.nih.gov/pubmed/17353253?ordinalpos=4&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum[/url]

Second, also from NIH: “Peripheral neuropathies associated with IgM monoclonal gammopathies, with or without reactivity to myelin-associated glycoprotein (MAG), are the most difficult cases to treat as there is not enough evidence for any treatment to be recommended .”

This may provide a clue as to why your insurance declined coverage.

The second article is here: [url]http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2707512/[/url]